Stay updated with breaking news from Phase Labs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investment analysts at StockNews.com began coverage on shares of ProPhase Labs (NASDAQ:PRPH – Get Rating) in a research note issued on Wednesday. The brokerage set a “strong-buy” rating on the stock. A number of other brokerages also recently issued reports on PRPH. HC Wainwright lowered their price objective on ProPhase Labs from $16.00 to $14.00 […]
ProPhase Labs (NASDAQ: PRPH) has recently received a number of price target changes and ratings updates: 6/14/2022 – ProPhase Labs is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 6/7/2022 – ProPhase Labs was upgraded by analysts at TheStreet from a “c+” rating to a “b” rating. 6/6/2022 – […]
DIDI jumped on the potential end of a regulatory probe. Solar stocks rose on tariff relief. PRAX dropped on clinical data. PRPH added to its 52-week high.
Analysts expect that ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating) will post $18.05 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for ProPhase Labs’ earnings, with the lowest sales estimate coming in at $13.39 million and the highest estimate coming in at $22.70 million. ProPhase Labs […]
Wall Street brokerages expect ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating) to report earnings per share of $0.17 for the current quarter, according to Zacks. Two analysts have issued estimates for ProPhase Labs’ earnings, with the highest EPS estimate coming in at $0.21 and the lowest estimate coming in at $0.12. ProPhase Labs reported earnings […]